AxoGen Inc. (AXGN) shares plummeted over 25% in pre-market trading on Wednesday following the company's fourth quarter results that missed expectations and a muted outlook for 2025.
The medical technology company focused on peripheral nerve repair reported revenue of $49.4 million for the fourth quarter of 2024, representing a 15.1% increase over the prior year. While this showed continued growth, it fell short of analysts' estimates.
Looking ahead, AxoGen provided full-year 2025 revenue guidance of 15-17% growth, which disappointed investors hoping for a more robust outlook after the company outlined an ambitious strategic plan targeting a 15-20% revenue CAGR over the next four years. Key growth initiatives included expanding in breast reconstruction, accelerating adoption in extremities and oral/maxillofacial markets, and developing new markets like nerve repair for prostatectomy procedures.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。